Hindustan Unilever Ltd
Hindustan Unilever Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Confident of better FY'27 performance than FY'26, expecting continued revenue growth driven by volume (Page 13, 22, 31). - Focus on competitive volume-led growth as top priority (Pages 13, 22). - Expect to navigate volatile input costs through pricing actions (2%-5% increases taken) and cost savings, maintaining EBITDA margins within guided band of 22.5%-23.5% (Pages 13, 21, 31). - Double-digit growth targeted in premium and growth portfolios such as Beauty & Wellbeing (Masstige portfolio at Rs. FY’27 outlook is positive with confidence in better performance than FY’26. - Topline growth expected, driven by volume-led growth and ongoing portfolio transformation. - Pricing actions (2-5% increases so far) will continue to manage cost inflation while balancing volume growth. - EBITDA margin guidance maintained in the band of 22.5% to 23.5%, with operating leverage and cost optimization. - Profit After Tax expected to grow, supported by volume growth and operational efficiencies. - Robust balance sheet and strong cash flows support sustainable investments and shareholder returns. - Key growth drivers include premiumization in Personal Care, expansion in Beauty & Wellbeing (e.g., Minimalist at Rs.
From Hindustan Unilever Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Confident of better FY'27 performance than FY'26, expecting continued revenue growth driven by volume (Page 13, 22, 31).
- Focus on competitive volume-led growth as top priority (Pages 13, 22).
- Expect to navigate volatile input costs through pricing actions (2%-5% increases taken) and cost savings, maintaining EBITDA margins within guided band of 22.5%-23.5% (Pages 13, 21, 31).
- Double-digit growth targeted in premium and growth portfolios such as Beauty & Wellbeing (Masstige portfolio at Rs. 1,200 crores ARR), Personal Care premium products, Home Care liquids, and Lifestyle Nutrition (Pages 7, 8, 10, 15).
- Expansion in penetration of niche formats in Skin Care (sunscreens, light moisturizers, face washes) and new segments like RTD and protein in Lifestyle Nutrition (Pages 29, 16).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Hindustan Unilever Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Hindustan Unilever Limited has planned a Rs. 2,000 crores capital expenditure focused on expanding capacity in premium formats across Home Care, Personal Care, and Beauty categories.
- The company has deployed Rs. 3,500 crores into bolt-on acquisitions to strengthen its presence in fast-evolving demand spaces, including digital-first premium Beauty & Wellbeing platforms like Minimalist and OZiva.
- The strategic investments reflect HUL's focus on building businesses of the future, emphasizing portfolio premiumization and growth acceleration.
- The capex and acquisitions are part of HUL's sharpened capital allocation to simultaneously fuel growth and sustain strong shareholder returns.
Fundraising & Capital Structure
See what Hindustan Unilever Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Hindustan Unilever Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹16.4K Cr, net profit ₹3.0K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Hind. Unilever's management said in earlier quarters
Others in Diversified FMCG this season
- ITC Ltd (Q4 FY26)
21,463 crore, up 17.5% YoY (Page 43) . Key concall takeaways from ITC Ltd's Q4 FY26 earnings call — and how it ranks against sector peers.
- Hindustan Foods (Q4 FY26)
Confident to achieve PAT of INR 200-220 crores for FY27, indicating 40-50% growth in PAT compared to FY26. Key concall takeaways from Hindustan Foods Ltd's Q4…
- Godavari Bioref. (Q4 FY26)
FY26 saw a profit after tax of INR 3.5 crores, a positive turnaround from a loss in FY25. Key concall takeaways from Godavari Biorefineries Ltd's Q4 FY26…
Frequently Asked Questions
What were Hindustan Unilever Ltd Q4 FY26 results?
Confident of better FY'27 performance than FY'26, expecting continued revenue growth driven by volume (Page 13, 22, 31). - Focus on competitive volume-led growth as top priority (Pages 13, 22). - Expect to navigate volatile input costs through pricing actions (2%-5% increases taken) and cost savings, maintaining EBITDA margins within guided band of 22.5%-23.5% (Pages 13, 21, 31). - Double-digit growth targeted in premium and growth portfolios such as Beauty & Wellbeing (Masstige portfolio at Rs. FY’27 outlook is positive with confidence in better performance than FY’26. - Topline growth expected, driven by volume-led growth and ongoing portfolio transformation. - Pricing actions (2-5% increases so far) will continue to manage cost inflation while balancing volume growth. - EBITDA margin guidance maintained in the band of 22.5% to 23.5%, with operating leverage and cost optimization. - Profit After Tax expected to grow, supported by volume growth and operational efficiencies. - Robust balance sheet and strong cash flows support sustainable investments and shareholder returns. - Key growth drivers include premiumization in Personal Care, expansion in Beauty & Wellbeing (e.g., Minimalist at Rs.
What is Hindustan Unilever Ltd share price analysis?
Hindustan Unilever Ltd currently shows a neutral. The stock trades at a P/E of 44.2 with a market cap of ₹488,010 Cr. Investors should review the full earnings analysis for detailed insights.
Is Hindustan Unilever Ltd planning capital expenditure?
Hindustan Unilever Limited has planned a Rs.
Keep Hindustan Unilever Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.